Corvus Pharmaceuticals, Inc. (CRVS) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 45.53M USD | Research and Development Expense |
| Revenue | (m) | |
| Stock-based compensation | 8.08M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -56.96M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $45.53M | (m) | $8.08M | $-56.96M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $37.44M | (m) | $6.73M | $-47.93M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $33.72M | (m) | $5.33M | $-42.97M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $29.75M | (m) | $4.57M | $-38.86M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $26.52M | (m) | $4.05M | $-35.54M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $22.76M | (m) | $3.56M | $-31.22M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $19.39M | (m) | $3.00M | $-27.55M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $17.41M | (m) | $2.76M | $-25.09M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $16.15M | (m) | $2.58M | $-23.40M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $16.01M | (m) | $2.34M | $-23.09M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $16.53M | (m) | $2.15M | $-23.41M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $16.61M | (m) | $2.19M | $-23.42M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $23.01M | (m) | $2.31M | $-30.34M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $23.96M | (m) | $2.44M | $-31.73M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $24.47M | (m) | $2.69M | $-32.56M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $25.18M | (m) | $2.81M | $-33.71M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $21.80M | (m) | $3.25M | $-30.28M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $25.98M | (m) | $3.75M | $-34.56M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $29.11M | (m) | $4.23M | $-38.63M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $31.52M | (m) | $4.73M | $-41.70M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $31.15M | (m) | $4.92M | $-42.50M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $29.90M | (m) | $5.13M | $-41.97M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $31.83M | (m) | $5.75M | $-43.76M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $33.56M | (m) | $6.26M | $-45.32M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $35.94M | (m) | $6.72M | $-46.99M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $38.72M | (m) | $7.24M | $-49.82M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $37.98M | (m) | $7.35M | $-48.85M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | $37.45M | (m) | $7.41M | $-48.59M | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $36.83M | (m) | $7.45M | $-48.22M | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $35.90M | (m) | $7.29M | $-46.88M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $38.59M | (m) | $7.13M | $-49.22M | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | $39.88M | (m) | $7.07M | $-50.24M | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | $42.24M | (m) | $6.78M | $-52.03M | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $44.91M | (m) | $6.56M | $-54.95M | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $46.30M | (m) | $6.23M | $-56.52M | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | $45.75M | (m) | $5.54M | $-55.59M | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $42.72M | (m) | $5.30M | $-53.12M | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $37.46M | (m) | $4.86M | $-46.77M | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $29.36M | (m) | $3.83M | $-36.98M | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $11.35M | (m) | $428.00K | $-13.77M | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |